SG11201506858SA - Acellular pertussis vaccine - Google Patents

Acellular pertussis vaccine

Info

Publication number
SG11201506858SA
SG11201506858SA SG11201506858SA SG11201506858SA SG11201506858SA SG 11201506858S A SG11201506858S A SG 11201506858SA SG 11201506858S A SG11201506858S A SG 11201506858SA SG 11201506858S A SG11201506858S A SG 11201506858SA SG 11201506858S A SG11201506858S A SG 11201506858SA
Authority
SG
Singapore
Prior art keywords
pertussis vaccine
acellular pertussis
acellular
vaccine
pertussis
Prior art date
Application number
SG11201506858SA
Other languages
English (en)
Inventor
Jan Theunis Poolman
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of SG11201506858SA publication Critical patent/SG11201506858SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201506858SA 2013-03-08 2014-03-06 Acellular pertussis vaccine SG11201506858SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08
EP13169328 2013-05-27
PCT/EP2014/054379 WO2014135651A1 (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Publications (1)

Publication Number Publication Date
SG11201506858SA true SG11201506858SA (en) 2015-09-29

Family

ID=48470836

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506858SA SG11201506858SA (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Country Status (22)

Country Link
US (2) US8916173B2 (es)
EP (1) EP2863943B1 (es)
JP (1) JP6282673B2 (es)
KR (1) KR102236498B1 (es)
CN (1) CN105007936B (es)
AP (1) AP2015008702A0 (es)
AU (1) AU2014224556B2 (es)
BR (1) BR112015021523A8 (es)
CA (1) CA2903937C (es)
CL (1) CL2015002513A1 (es)
DK (1) DK2863943T3 (es)
EA (1) EA030749B1 (es)
ES (1) ES2597832T3 (es)
IL (1) IL241271A (es)
MX (1) MX362793B (es)
MY (1) MY172181A (es)
NZ (1) NZ630868A (es)
PE (1) PE20151720A1 (es)
PH (1) PH12015501875A1 (es)
SG (1) SG11201506858SA (es)
TW (1) TWI630915B (es)
WO (1) WO2014135651A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
KR102426041B1 (ko) 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
KR102362777B1 (ko) 2018-03-27 2022-02-15 주식회사 녹십자 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법
JP7469302B2 (ja) * 2018-11-06 2024-04-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
AU2021236055A1 (en) * 2020-03-09 2022-10-20 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
WO2024064579A1 (en) * 2022-09-20 2024-03-28 Ohio State Innovation Foundation Immunogenic proteins from bordetella pertussis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3528006A1 (de) 1985-08-05 1987-02-05 Degussa Verfahren zur herstellung von epoxidierten organosiliziumverbindungen
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
DE3781541T2 (de) 1986-12-23 1993-05-06 Univ Leland Stanford Junior Modifiziertes pertussistoxin.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
JP2918895B2 (ja) 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
US7144576B1 (en) 1987-09-04 2006-12-05 Amgen, Inc. Modified pertussis toxin
IT1223334B (it) 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA1341123C (en) 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
EP0396964B1 (en) 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
ATE134194T1 (de) 1989-11-06 1996-02-15 Smithkline Beecham Biolog Verfahren
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
ATE129159T1 (de) 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6444211B2 (en) 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
AU662783B2 (en) 1992-01-08 1995-09-14 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Whooping cough vaccine
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
ES2118963T3 (es) 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DE69327534T2 (de) 1992-06-18 2000-06-08 Harvard College Impfstoffe gegen diphtherietoxin
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FI951970A (fi) 1995-04-25 1996-10-26 Borealis As Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
DK0824358T3 (da) 1995-05-04 2003-01-27 Aventis Pasteur Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
JP3280675B2 (ja) * 1996-07-02 2002-05-13 コノート ラボラトリーズ リミテッド 多価ｄｔｐポリオワクチン
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6475754B1 (en) 1999-05-14 2002-11-05 University Of Tennessee Research Corporation Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor
CA2783274C (en) 2000-06-29 2018-08-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition with reduced dose of haemophilus influenza type b
EP1174505A1 (en) * 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
GB0018031D0 (en) 2000-07-21 2000-09-13 Microbiological Res Authority Improvements relating to vaccines containing bordetella pertussis antigen
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
ES2484093T3 (es) 2009-07-16 2014-08-11 Crucell Holland B.V. Producción de poliovirus con títulos elevados para producción de vacunas
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante

Also Published As

Publication number Publication date
US20150086586A1 (en) 2015-03-26
MX2015011879A (es) 2016-01-08
JP6282673B2 (ja) 2018-02-21
BR112015021523A8 (pt) 2021-06-29
CN105007936A (zh) 2015-10-28
WO2014135651A1 (en) 2014-09-12
IL241271A (en) 2016-07-31
BR112015021523A2 (pt) 2017-07-18
CA2903937A1 (en) 2014-09-12
AP2015008702A0 (en) 2015-09-30
EA030749B1 (ru) 2018-09-28
EP2863943B1 (en) 2016-07-13
TWI630915B (zh) 2018-08-01
CL2015002513A1 (es) 2016-05-27
CA2903937C (en) 2021-11-09
JP2016510056A (ja) 2016-04-04
KR102236498B1 (ko) 2021-04-06
AU2014224556A1 (en) 2015-09-17
US8916173B2 (en) 2014-12-23
IL241271A0 (en) 2015-11-30
ES2597832T3 (es) 2017-01-23
US20140255446A1 (en) 2014-09-11
CN105007936B (zh) 2018-10-02
EA201591663A1 (ru) 2016-01-29
PE20151720A1 (es) 2015-12-10
NZ630868A (en) 2017-02-24
TW201440786A (zh) 2014-11-01
AU2014224556B2 (en) 2016-10-06
KR20150124973A (ko) 2015-11-06
MX362793B (es) 2019-02-13
DK2863943T3 (en) 2016-11-07
MY172181A (en) 2019-11-15
EP2863943A1 (en) 2015-04-29
PH12015501875A1 (en) 2015-12-07

Similar Documents

Publication Publication Date Title
IL276210B1 (en) Mers-cov vaccine
IL279395A (en) A vaccine
HK1226440A1 (zh) Cmv疫苗
HRP20181376T1 (hr) Poboljšana cjepiva protiv poksvirusa
IL266651B (en) graft
GB201321242D0 (en) Immunogenic compound
HK1218872A1 (zh) 乙型肝炎疫苗
IL241271A (en) Al-Thai pertussis vaccine
GB201315946D0 (en) Oncology vaccine
DK2976355T3 (en) Vaccines against chlamydia sp
HK1218877A1 (zh) 粘膜疫苗組合物
PT3007725T (pt) Beta-glicolípidos para utilização como adjuvantes
HK1217206A1 (zh) 疫苗
GB201309664D0 (en) Fish vaccine
HK1219054A1 (zh) 粘膜疫苗組合物
GB201301119D0 (en) Viral vaccines
ZA201506581B (en) Acellular pertussis vaccine
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
GB201320421D0 (en) Conjugated vaccine
IL230230A0 (en) graft
GB201310756D0 (en) Implant